Lyell Immunopharma (LYEL) EBT Margin (2020 - 2026)

Lyell Immunopharma has reported EBT Margin for 7 years, with the latest figure at 5160800.0% in Q1 2026.

• Quarterly EBT Margin fell 331961429.0% year-over-year to 5160800.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1501754.84% (down 4971484.0% YoY) and the FY2025 annual result came in at 795952.78%, up 38078493.0% from the prior year.
• EBT Margin declined to 5160800.0% in Q1 2026 per LYEL's latest filing, from 2411550.0% in the prior quarter.
• Over five years, EBT Margin peaked at 28.02% in Q4 2022 and troughed at 6279266.67% in Q3 2022.
• A 5-year average of 1759631.73% and a median of 995992.31% in 2024 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2022 and 2023: EBT Margin sank 627706536 bps in 2022, then surged 599906667 bps in 2023.
• Over 5 years, EBT Margin stood at 28.02% in 2022, then sank by 8423430 bps to 2360315.38% in 2023, then plunged by 116 bps to 5100509.09% in 2024, then surged by 53 bps to 2411550.0% in 2025, then tumbled by 114 bps to 5160800.0% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 5160800.0%, 2411550.0%, and 681120.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.